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Western blot analysis was performed as described previously (Kobayashi et al., 20% glycerol, 0.004% BPB and 9 M urea and separated on 4.5% stacking and 10% SDS The human MRP2 promoter (-1200/+15) was amplified by PCR from human 164 genomic DNA and then subcloned into a pGL3-basic vector (Promega, Madison, WI).
165
Four 5'-deletion fragments (-701/+15, -427/+15 and -85/+15) were generated from
166
-1200/+15 by the PCR amplification method and subcloned into a pGL3-basic vector.
167
Four different forward primers each contained an internal site for XhoⅠrestriction LXRβ (Shinar et al., 1994; Willy et al., 1995; Miyata et al., 1996) . Previous studies have hand, SREBP-2 localized to the nuclei with or without TO901317 and statins (Fig. 4B) .
282
These results suggest that pitavastatin induces SREBP-1 activation and increases MRP2 
Conclusions

296
In conclusion, our data demonstrated that pitavastatin upregulated MRP2
297
expression by an LXR-SREBP regulatory pathway in hepatocytes. Our findings suggest 298 that LXR and SREBP can be involved in the up-regulation of MRP2 expression in 299 hepatocytes.
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428
Data shown are typical results of the three independent experiments.
429
The intensity of Western blot analysis was determined by densitometry using Scion 
440
(A) HepG2 cells were treated with 10 µM TO901317 and pitavastatin for 24 h.
441
Localization of LXRα/β was determined using an antibody against LXRα/β (green).
442
Nuclei were stained with DAPI (blue). Scale bar shows 10 µm.
443
Data shown are typical results of three independent experiments.
444
(B) A series of MRP2 deletion promoter constructs were transfected into HepG2 cells 445 for luciferase assay.
446
HepG2 cells were treated with 10 µM TO901317.
447
The bar graphs (n=4-6) are given as means with S.D. of more than two independent 448 experiments. 
455
These labeled SREs were incubated with nuclear extracts from HepG2 cells.
456
HepG2 cells were treated with various concentrations of TO901317 for 24 h.
457
Data shown are typical results of the more than two independent experiments. of SREBP-1 and 2 was determined using an antibody against SREBP-1 and 2
466
(green). Nuclei were stained with DAPI (blue).
467
Data shown are typical results of the more than two independent experiments. 
474
HepG2 cells were treated with 10 µM TO901317 and pitavastatin for 3 and 6 hours. 
